It is well-established that PD-L1 expression can be induced by IFNγ signaling leading to tumor adaptive resistance to immunotherapy.
Although other immunosuppressive mechanisms may be involved, these observations suggest that immunostimulatory cytokines produced by activated CAR T cells can induce GBM adaptive resistance pathways, such as PD-L1 induction, and hinder tumor eradication by CAR T cells.
Our results lead to the potential of correlating tumor IFNγ receptor expression with CLTX-CAR T cell therapeutic effect, as well as the possibility of combining CLTX-CAR T cells with checkpoint inhibitors for more effective GBM clearances.
Guessing that they are going with CLTX effect only - and the outcome will be heavily determined by how much PD-L1 expression there is. Low in vivo numbers here, and still a clear effect in the worst case scenario (high PD-L1).
A/B is low (PBT106)
C/D is high (PBT 003-4)
- Forums
- ASX - By Stock
- CHM
- CLTX-CAR T is a game changer
CLTX-CAR T is a game changer, page-14
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.76M |
Open | High | Low | Value | Volume |
1.8¢ | 1.9¢ | 1.8¢ | $7.224K | 394.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 524782 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.9¢ | 579591 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 524782 | 0.018 |
3 | 707660 | 0.017 |
12 | 3472701 | 0.016 |
13 | 4840065 | 0.015 |
5 | 2331428 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 579591 | 4 |
0.020 | 1114755 | 4 |
0.021 | 488333 | 3 |
0.022 | 300000 | 2 |
0.023 | 155000 | 2 |
Last trade - 15.32pm 12/07/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |